Synthorx Inc (THOR) Receives Consensus Recommendation of “Strong Buy” from Analysts
Synthorx Inc (NASDAQ:THOR) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.
Brokerages have set a 1-year consensus price target of $26.67 for the company and are predicting that the company will post ($0.32) earnings per share for the current quarter, according to Zacks. Zacks has also given Synthorx an industry rank of 64 out of 255 based on the ratings given to related companies.
A number of research analysts recently commented on THOR shares. Jefferies Financial Group initiated coverage on Synthorx in a research note on Wednesday, January 2nd. They issued a “buy” rating and a $21.00 target price on the stock. Leerink Swann initiated coverage on shares of Synthorx in a research report on Friday, March 15th. They set an “outperform” rating for the company. HC Wainwright initiated coverage on shares of Synthorx in a research report on Wednesday, January 2nd. They set a “buy” rating and a $30.00 price target for the company. Svb Leerink restated an “outperform” rating on shares of Synthorx in a research report on Monday, March 18th. Finally, Zacks Investment Research upgraded shares of Synthorx from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Saturday, March 16th.
THOR traded up $0.53 during trading on Tuesday, reaching $17.90. The stock had a trading volume of 67,089 shares, compared to its average volume of 133,020. The stock has a market cap of $543.93 million and a PE ratio of -2.72. Synthorx has a one year low of $11.00 and a one year high of $23.53.
Synthorx (NASDAQ:THOR) last released its earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.89) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.77). As a group, equities research analysts predict that Synthorx will post -1.46 EPS for the current year.
Synthorx Company Profile
Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.
Featured Story: Should You Consider an Index Fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.